LONDON (Thomson Financial) - Taihua Plc. said sales volumes of Paclitaxel
and Homoharringtonine in the six months to June 30 are ahead of last year, but
adverse exchange rate fluctuations between the Renminbi and the U.S. dollar have
impacted the value of sales.
The biotechnology company said that though new traditional Chinese medicines
are ready for introduction into the market, licences issued to Chinese companies
since 2005 are under review, which has led to a suspension of production.
The company added that feedback from the European Directorate for the
Quality of Medicines on its application for a certificate of suitability for
Paclitaxel is expected before the end of the year.
TFN.newsdesk@thomson.com
ans/rfw
COPYRIGHT
Copyright Thomson Financial News Limited 2008. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.
|